Open AccessThe frequency and characteristics of cardiovascular pathology in HIV-infected patients (according to aytopsy)
Author(s) -
В. С. Голышко,
V. A. Snezhitskiy,
N. V. Matsiyeueskaya,
Н. И. Прокопчик
Publication year - 2017
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-10-928-934
Subject(s) - medicine , autopsy , myocarditis , confidence interval , heart failure , concomitant , endocarditis , retrospective cohort study , cardiomyopathy , gastroenterology , pericardial effusion , cause of death , surgery , disease
Aim to study the frequency and structure of the cardiovascular diseases (CVD) deaths from HIV-infected patients. A retrospective analysis of medical records of 346 deaths of HIV-infected patients: 225 (65%) males (95% confidence interval - 95% CI 69,8-58,8) and 121 (35%) women (95% CI 30,1-40,1) at the age of 35.0 [32,0;38,0] years. Autopsy was performed in 150 (43,5%) patients (95% CI 38,2-48,6). GCC is installed in 77 (22.3 %) of 346 cases (95% CI of 18.2-26.9) . While 18 (5,2%) patients (95% CI 3,3-8,1) CVD was the main cause of death in 59 (17,1%) - concomitant diseases (95% CI 13,5-1,4). The structure of the CVD were presented with acute heart failure in 17 (4,9%) autopsy cases (95% CI 3,1-7,7) , hydropericardium - 14 (4.0%) of cases (95% CI 2,4-6,7), coronary heart disease in 14 (4.0%) of cases (95% CI 2,4-6,7), cardiomyopathy in 11 (3,2%) cases (95% CI 1,8-5,6), myocarditis in 10 (2.9%) cases (95% CI 1,6-5,2), infective endocarditis in 4 (1.2%) cases (95% CI 0.5-3.0), chronic pulmonary heart, in 4 (1.2%) cases (95% CI 0.5-3.0), effusion in 3 (0.9%) cases (95% CI 0,3 - 2,5). The defeat of the cardiovascular system in HIV-infected patients in 79,2% of cases were formed against the background of generalized of severe opportunistic infections and diseases. In patients not receiving antiretroviral therapy, have higher rates of death AIDS-associated CVD as compared to that in patients receiving therapy: 3,8% (95% CI 1.9-7,3) and 0 respectively (p=0.05).